PPARGC1A and colonic neoplasm: SIRT3 has been confirmed to enhance chemotherapy resistance of colon cancer by modulating the acetylation of superoxide dismutase 2 (SOD2) and peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PGC-1α), which enabled SIRT3 to be an independent prognostic factor for colon cancer (Paku et al., 2021).